p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer
- 29 January 2003
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 82 (2), 111-120
- https://doi.org/10.1002/jso.10186
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- p53, the Cellular Gatekeeper for Growth and DivisionCell, 1997
- Elevation of intracellular cyclic adenosine monophosphate inhibits the epidermal growth factor signal transduction pathway and cellular growth in pancreatic adenocarcinoma cell linesSurgery, 1996
- Pancreatic carcinoma in perspective: A continuing challengeCancer, 1996
- p53 in signaling checkpoint arrest or apoptosisCurrent Opinion in Genetics & Development, 1996
- Association of p53 Gene Mutations with Short Survival in Pancreatic AdenocarcinomaJapanese Journal of Cancer Research, 1995
- K‐ras and p53 Alterations in Genomic DNA and Transcripts of Human Pancreatic Adenocarcinoma Cell LinesJapanese Journal of Cancer Research, 1994
- p53: At the Crossroads of Molecular Carcinogenesis and Risk SssessmentScience, 1993
- p53 Mutations are common in pancreatic cancer and are absent in chronic pancreatitisCancer Letters, 1993
- Abnormalities of the p53 tumour suppressor gene in human pancreatic cancerBritish Journal of Cancer, 1991
- The p53 tumour suppressor geneNature, 1991